Brokerages Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Target Price at $27.40

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has received an average recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $27.40.

Several equities research analysts recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 15th.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ KMTS opened at $26.43 on Wednesday. The company has a market cap of $1.54 billion, a PE ratio of -6.67 and a beta of 0.83. Kestra Medical Technologies has a 12 month low of $13.25 and a 12 month high of $30.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The company has a 50-day simple moving average of $21.05 and a 200-day simple moving average of $22.77.

Insider Buying and Selling

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider directly owned 395,467 shares of the company’s stock, valued at $8,229,668.27. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold 45,000 shares of company stock worth $927,150 in the last ninety days. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter. Rhumbline Advisers lifted its position in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after buying an additional 874 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies during the fourth quarter valued at approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its position in Kestra Medical Technologies by 34.6% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after buying an additional 1,392 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.